The novel oral anticoagulants: A new frontier
ثبت نشده
چکیده
“A ctionable” oncogenic drivers – genetic mutations that are critical to the development and maintenance of a cancer and that are susceptible to targeted therapy – were identified in 64% of tumor samples from 733 patients with lung adenocarcinoma in a proof-ofconcept study aimed at determining the frequency of such mutations that was reported in JAMA. The researchers used multiplexed genetic testing to screen tumor samples for 10 possible oncogenic drivers simultaneously. In some cases, the results allowed clinicians to individually tailor cancer treatment, and patients who received this targeted therapy showed longer survival times than PULMONARY PERSPECTIVES
منابع مشابه
An Overview of Novel Anticoagulants
Arterial and venous thromboembolism is one of the most common causes of death worldwide. For almost seventy years, heparin, low molecular weight heparin, and vitamin K antagonists have been widely used in the prevention and treatment of thromboembolic disorders. However, many of the limitations of these traditional anticoagulants have led to the search for and attempts to introduce better drug ...
متن کاملOral anticoagulation pdf
New oral anticoagulants: a practical guide on prescription, laboratory. The prescription of new oral anticoagulants NOAC. Label2012202155s000lbl.pdf.Oral anticoagulants OACs are used for the prevention of embolus in atrial. Www.sspcrs.ielibrhtmlOralAnticoagulantIndividualReimbursemenApplication.pdf.oral anticoagulants Baglin Rose, 1998 Baglin et al, 2006. Anticoagulation control but results in ...
متن کاملDental management of patients taking novel oral anticoagulants (NOAs): Dabigatran
BACKGROUND A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years. Patients being treated with oral anticoagulants are at higher risk for bleeding when undergoing dental treatments. MATERIAL AND METHODS A literature search was conducted...
متن کاملRole of Novel Oral Anticoagulants in Primary and Secondary Thromboprophylaxis in Cancer
The development of venous thromboembolism is one of the major causes of morbidity and mortality in patients with cancer. The standard treatment of deep venous thrombosis or pulmonary embolism occurring in patients with active malignancy remains the use of low molecular weight heparins. However, in clinical practice, practitioners are frequently asked about the efficacy and safety of various new...
متن کاملThe New Oral Anticoagulants for the Treatment of Venous Thromboembolism: A New Paradigm Shift in Antithrombotic Therapy
BACKGROUND Several novel oral anticoagulants have been studied for the prevention and treatment of venous thromboembolism (VTE) in different patient populations. Clinicians will increasingly encounter scenarios in which they must choose among these and conventional anticoagulants for the treatment of this potentially fatal condition. OBJECTIVE To review the results of Phase III clinical trial...
متن کامل